Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Antigen Presentation
B7-H1 Antigen
/ genetics
CD8-Positive T-Lymphocytes
/ immunology
Down-Regulation
/ immunology
Gene Expression Regulation, Neoplastic
/ immunology
HEK293 Cells
HeLa Cells
Histocompatibility Antigens Class I
/ genetics
Humans
Interferon Regulatory Factor-2
/ deficiency
Neoplasm Proteins
/ genetics
Neoplasms
/ genetics
Tumor Escape
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
29
04
2019
accepted:
01
08
2019
pubmed:
1
9
2019
medline:
19
5
2020
entrez:
1
9
2019
Statut:
ppublish
Résumé
To arise and progress, cancers need to evade immune elimination. Consequently, progressing tumors are often MHC class I (MHC-I) low and express immune inhibitory molecules, such as PD-L1, which allows them to avoid the main antitumor host defense, CD8
Identifiants
pubmed: 31471524
pii: jimmunol.1900475
doi: 10.4049/jimmunol.1900475
pmc: PMC6761035
mid: NIHMS1536996
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Histocompatibility Antigens Class I
0
IRF2 protein, human
0
Interferon Regulatory Factor-2
0
Neoplasm Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1999-2010Subventions
Organisme : NIAID NIH HHS
ID : R01 AI114495
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145932
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI095213
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM107000
Pays : United States
Informations de copyright
Copyright © 2019 by The American Association of Immunologists, Inc.
Références
Mol Med Today. 1999 Apr;5(4):178-86
pubmed: 10203751
Adv Immunol. 2000;74:181-273
pubmed: 10605607
Eur J Immunol. 2000 Aug;30(8):2333-43
pubmed: 10940924
Blood. 2001 Jan 1;97(1):192-7
pubmed: 11133760
Nature. 2001 Apr 26;410(6832):1107-11
pubmed: 11323675
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Nature. 2002 Oct 3;419(6906):480-3
pubmed: 12368856
Nat Immunol. 2002 Dec;3(12):1169-76
pubmed: 12436109
J Biol Chem. 2003 Jul 11;278(28):25401-7
pubmed: 12738767
Mol Cell Biol. 2004 Jul;24(14):6298-310
pubmed: 15226432
Physiology (Bethesda). 2004 Aug;19:216-24
pubmed: 15304636
J Immunol. 2005 Apr 1;174(7):3948-58
pubmed: 15778351
FEBS Lett. 2006 Feb 6;580(3):755-62
pubmed: 16413538
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
J Immunol. 2007 Dec 1;179(11):7614-23
pubmed: 18025207
Cancer Res. 1991 May 1;51(9):2463-8
pubmed: 1849792
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
Immunogenetics. 2008 Aug;60(8):439-47
pubmed: 18545995
Nucleic Acids Res. 1991 Aug 25;19(16):4421-8
pubmed: 1886766
J Immunol. 2009 Nov 1;183(9):5526-36
pubmed: 19828632
J Immunol. 1990 Aug 1;145(3):804-11
pubmed: 2115542
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nucleic Acids Res. 2012 Jan;40(Database issue):D130-5
pubmed: 22121212
Nat Immunol. 2011 Dec 25;13(2):129-35
pubmed: 22197977
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Int J Cancer. 2014 Jan 1;134(1):102-13
pubmed: 23784959
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Science. 2014 Mar 7;343(6175):1246949
pubmed: 24604202
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Cell. 1989 Aug 25;58(4):729-39
pubmed: 2475256
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Nucleic Acids Res. 2014 Dec 16;42(22):e168
pubmed: 25300484
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell Biosci. 2015 Apr 18;5:17
pubmed: 25960866
PLoS Genet. 2015 Jul 09;11(7):e1005375
pubmed: 26158850
Clin Cancer Res. 2016 Jan 15;22(2):470-8
pubmed: 26373575
J Thorac Oncol. 2016 Jul;11(7):964-75
pubmed: 27117833
Science. 2016 Jul 22;353(6297):399-403
pubmed: 27463676
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Oncoimmunology. 2016 Oct 20;5(12):e1247135
pubmed: 28123883
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Oncotarget. 2017 May 31;8(35):59901-59914
pubmed: 28938692
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Future Sci OA. 2017 Sep 04;3(4):FSO244
pubmed: 29134128
Mol Immunol. 2019 Sep;113:16-21
pubmed: 29224918
J Immunol. 2018 Jan 15;200(2):392-399
pubmed: 29311380
EMBO J. 2019 Jan 3;38(1):
pubmed: 30396996
iScience. 2018 Dec 21;10:247-264
pubmed: 30553813
Nature. 1995 Sep 28;377(6547):362-5
pubmed: 7566094
Mol Cell Biol. 1993 Aug;13(8):4531-8
pubmed: 7687740
Science. 1994 Jun 3;264(5164):1415-21
pubmed: 8197455
Eur J Immunol. 1996 Aug;26(8):1844-50
pubmed: 8765030
J Immunol. 1997 Mar 15;158(6):2723-30
pubmed: 9058806
J Immunol. 1997 May 1;158(9):4260-9
pubmed: 9126988
Scand J Immunol. 1997 May;45(5):463-70
pubmed: 9160088
Immunity. 1997 Jun;6(6):715-26
pubmed: 9208844
J Cell Biol. 1998 Mar 9;140(5):1265-76
pubmed: 9490737
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188